Keros Therapeutics Reports Stronger-Than-Expected Quarterly Earnings

Keros Therapeutics (NASDAQ:KROS) released its quarterly earnings results on Wednesday. The company reported an earnings per share (EPS) of ($1.14) for the latest quarter, which surpassed the analysts' consensus estimate of ($1.36) by $0.22. This positive surprise highlights Keros Therapeutics' ability to exceed expectations in a challenging market. Despite this the company faced significant financial challenges, presenting a negative net margin of 27,890.94% and a return on equity of -41.74%.

Keros Therapeutics Stock Activity:

Stock Performance Overview

During trading on Wednesday, shares of Keros Therapeutics rose by $0.03, reaching a price of $10.94. The trading volume was 1,257,944 shares, which is below the average volume of 1,614,620 shares. The company's current market capitalization stands at $443.15 million. Keros Therapeutics has a negative price-to-earnings (P/E) ratio of -2.10 and a beta of 1.39, indicating its volatility in the market. Over the past year, the stock has a low of $9.77 and a high of $73.00. The 50-day moving average is $12.88, while the 200-day moving average is $40.20.

Recent Changes in Analyst Ratings

Several analysts have recently provided their insights on Keros Therapeutics. Piper Sandler reduced its price target on the stock from $40.00 to $15.00 and maintained an “overweight” rating in a note released on January 17th. Similarly, Wedbush downgraded Keros from an “outperform” rating to “neutral” and lowered their price target from $47.00 to $15.00 on the same date. Cantor Fitzgerald also adjusted their rating from “overweight” to “neutral.” Furthermore, Guggenheim confirmed a “neutral” rating on January 17th, while Truist Financial cut their target price from $100.00 to $43.00 and maintained a “buy” rating. Overall, six analysts rated Keros with a hold, and eight gave it a buy rating. Currently, the average rating for the company is “Moderate Buy,” with a consensus price target set at $52.56.

Understanding Keros Therapeutics

About Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative therapies. These therapies are aimed at treating disorders associated with dysfunctional signaling from the transforming growth factor-beta family of proteins. The company's leading product candidate is KER-050, which is being researched for its potential to treat low blood cell counts, known as cytopenias, including anemia and thrombocytopenia, especially in patients suffering from myelodysplastic syndromes and myelofibrosis.

Conclusion

While Keros Therapeutics has shown strength by beating earnings expectations, the company continues to deal with significant financial hurdles. Investors and analysts will be watching the company closely as they navigate their future direction.

Keros, Earnings, Stocks